DE69431193D1 - Hiv - protease inhibitoren - Google Patents

Hiv - protease inhibitoren

Info

Publication number
DE69431193D1
DE69431193D1 DE69431193T DE69431193T DE69431193D1 DE 69431193 D1 DE69431193 D1 DE 69431193D1 DE 69431193 T DE69431193 T DE 69431193T DE 69431193 T DE69431193 T DE 69431193T DE 69431193 D1 DE69431193 D1 DE 69431193D1
Authority
DE
Germany
Prior art keywords
inhibitoren
hiv
protease
protease inhibitoren
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69431193T
Other languages
English (en)
Other versions
DE69431193T2 (de
Inventor
A Dressman
E Fritz
Marlys Hammond
J Hornback
W Kaldor
J Kalish
E Munroe
Heinz Reich
H Tatlock
A Shepherd
J Rodriguez
N Jungheim
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Agouron Pharmaceuticals LLC
Original Assignee
Agouron Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agouron Pharmaceuticals LLC filed Critical Agouron Pharmaceuticals LLC
Application granted granted Critical
Publication of DE69431193D1 publication Critical patent/DE69431193D1/de
Publication of DE69431193T2 publication Critical patent/DE69431193T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
    • C07C237/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/60—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton with the carbon atom of at least one of the carboxyl groups bound to nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/40—Acylated substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/50—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/06—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with the ring nitrogen atom acylated by carboxylic or carbonic acids, or with sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/576—Six-membered rings
    • C07F9/62—Isoquinoline or hydrogenated isoquinoline ring systems
DE69431193T 1993-10-07 1994-10-07 Hiv - protease inhibitoren Expired - Lifetime DE69431193T2 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US13354393A 1993-10-07 1993-10-07
US13369693A 1993-10-07 1993-10-07
US08/190,764 US5484926A (en) 1993-10-07 1994-02-02 HIV protease inhibitors
PCT/US1994/011307 WO1995009843A1 (en) 1993-10-07 1994-10-07 Hiv protease inhibitors

Publications (2)

Publication Number Publication Date
DE69431193D1 true DE69431193D1 (en) 2002-09-19
DE69431193T2 DE69431193T2 (de) 2002-12-12

Family

ID=27384442

Family Applications (3)

Application Number Title Priority Date Filing Date
DE69434214T Expired - Lifetime DE69434214T2 (de) 1993-10-07 1994-10-07 HIV protease inhibitoren
DE69434977T Expired - Lifetime DE69434977T2 (de) 1993-10-07 1994-10-07 HIV Protease Inhibitoren
DE69431193T Expired - Lifetime DE69431193T2 (de) 1993-10-07 1994-10-07 Hiv - protease inhibitoren

Family Applications Before (2)

Application Number Title Priority Date Filing Date
DE69434214T Expired - Lifetime DE69434214T2 (de) 1993-10-07 1994-10-07 HIV protease inhibitoren
DE69434977T Expired - Lifetime DE69434977T2 (de) 1993-10-07 1994-10-07 HIV Protease Inhibitoren

Country Status (36)

Country Link
US (14) US5484926A (de)
EP (3) EP0889036B1 (de)
JP (2) JP2951724B2 (de)
KR (1) KR100190517B1 (de)
CN (2) CN1046269C (de)
AP (1) AP600A (de)
AT (3) ATE362918T1 (de)
AU (1) AU694746B2 (de)
BG (1) BG62567B1 (de)
BR (1) BR9407782A (de)
CA (2) CA2268709C (de)
CZ (1) CZ290417B6 (de)
DE (3) DE69434214T2 (de)
DK (2) DK0722439T3 (de)
EE (1) EE05399B1 (de)
ES (3) ES2287387T3 (de)
FI (1) FI114794B (de)
GE (2) GEP20002209B (de)
HK (3) HK1013650A1 (de)
HU (2) HU227885B1 (de)
MD (1) MD1507G2 (de)
MY (1) MY138860A (de)
NO (1) NO307050B1 (de)
NZ (2) NZ329626A (de)
OA (1) OA10718A (de)
PL (1) PL185647B1 (de)
PT (2) PT889036E (de)
RO (1) RO119363B1 (de)
RU (1) RU2139280C1 (de)
SI (2) SI0722439T1 (de)
SK (2) SK284116B6 (de)
TJ (1) TJ339B (de)
TW (1) TW432049B (de)
UA (1) UA56984C2 (de)
UY (1) UY23840A1 (de)
WO (1) WO1995009843A1 (de)

Families Citing this family (146)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6878728B1 (en) 1999-06-11 2005-04-12 Vertex Pharmaceutical Incorporated Inhibitors of aspartyl protease
US20040122000A1 (en) 1981-01-07 2004-06-24 Vertex Pharmaceuticals Incorporated. Inhibitors of aspartyl protease
USH1649H (en) * 1987-07-31 1997-05-06 Barrish; Joel C. HIV protease inhibitor combinations
EP0810209B1 (de) 1992-08-25 2002-06-05 G.D. Searle & Co. Hydroxyethylaminosulfonamide verwendbar als Inhibitoren retroviraler Proteasen
US7141609B2 (en) 1992-08-25 2006-11-28 G.D. Searle & Co. α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors
US5484926A (en) * 1993-10-07 1996-01-16 Agouron Pharmaceuticals, Inc. HIV protease inhibitors
US5514801A (en) * 1992-12-29 1996-05-07 Monsanto Company Cyclic sulfone containing retroviral protease inhibitors
IL110255A (en) * 1993-07-16 1998-12-06 Merck & Co Inc Creation and resolution of 2 tert-butylcarboxamidopiprazine
ES2153434T3 (es) * 1994-02-02 2001-03-01 Lilly Co Eli Inhibidores de la proteasa del vih y sus intermedios.
US5480887A (en) * 1994-02-02 1996-01-02 Eli Lilly And Company Protease inhibitors
US5461154A (en) * 1994-02-02 1995-10-24 Eli Lilly And Company Intermediate and process for making
US20030207813A1 (en) * 1996-12-09 2003-11-06 G.D. Searle Retroviral protease inhibitor combinations
UA49803C2 (uk) * 1994-06-03 2002-10-15 Дж.Д. Сьорль Енд Ко Спосіб лікування ретровірусних інфекцій
US5831117A (en) * 1995-01-20 1998-11-03 G. D. Searle & Co. Method of preparing retroviral protease inhibitor intermediates
US6037157A (en) 1995-06-29 2000-03-14 Abbott Laboratories Method for improving pharmacokinetics
ATE288891T1 (de) 1995-09-26 2005-02-15 Japan Tobacco Inc Verfahren zur herstellung von amid-derivaten und ihren zwischenverbindungen
DE69637770D1 (de) * 1995-09-26 2009-01-15 Agouron Pharma Verfahren zur herstellung von amidderivaten und ihren zwischenverbindungen
US5914332A (en) 1995-12-13 1999-06-22 Abbott Laboratories Retroviral protease inhibiting compounds
MY126358A (en) * 1996-03-22 2006-09-29 Glaxo Group Ltd Compositions comprising vx478 and a water soluble tocopherol derivative such as vitamin e-tpgs
EP0844587B1 (de) * 1996-06-05 2004-11-24 Sega Enterprises, Ltd. Bild-prozessor, bildverarbeitungsverfahren, spielcomputer und aufzeichnungsmedium
US5925759A (en) 1996-09-05 1999-07-20 Agouron Pharmaceuticals, Inc. Methods of making HIV-protease inhibitors and intermediates for making HIV-protease inhibitors
US5962725A (en) 1996-09-05 1999-10-05 Agouron Pharmaceuticals, Inc. Intermediate compounds useful for making HIV protease inhibitors such as nelfinavir
US5705647A (en) * 1996-09-05 1998-01-06 Agouron Pharmaceuticals, Inc. Intermediates for making HIV-protease inhibitors
UA67727C2 (uk) * 1996-09-05 2004-07-15 Агурон Фармасевтікелс, Інк. Проміжні сполуки для одержання інгібіторів віл-протеази і способи одержання інгібіторів віл-протеази
US6232333B1 (en) 1996-11-21 2001-05-15 Abbott Laboratories Pharmaceutical composition
DE19704885C1 (de) * 1997-02-11 1998-06-10 Clariant Gmbh Verfahren zur Herstellung von 3-Hydroxy-2-methylbenzoesäure und 3-Acetoxy-2-methylbenzoesäure
HRP980112A2 (en) * 1997-03-13 1998-12-31 Agouron Pharma Hiv protease inhibitors
US6001851A (en) * 1997-03-13 1999-12-14 Agouron Pharmaceuticals, Inc. HIV protease inhibitors
US6130348A (en) 1997-04-10 2000-10-10 Hoffmann-La Roche Inc. Process for a phenylthiobutyl-isoquinoline and intermediates therefor
DE69812079T2 (de) * 1997-04-10 2003-12-18 Hoffmann La Roche Verfahren zur herstellung eines buthylthuio-isochinolinderivates und zwischenprodukte dafür
US6123694A (en) * 1997-05-09 2000-09-26 Paragon Trade Brands Disposable absorbent article with unitary leg gathers
DE19730602A1 (de) * 1997-07-17 1999-01-21 Clariant Gmbh 3-Acetoxy-2-methylbenzoesäurechlorid und ein Verfahren zu seiner Herstellung
US6084107A (en) * 1997-09-05 2000-07-04 Agouron Pharmaceuticals, Inc. Intermediates for making HIV-protease inhibitors
US6436989B1 (en) 1997-12-24 2002-08-20 Vertex Pharmaceuticals, Incorporated Prodrugs of aspartyl protease inhibitors
IN188157B (de) 1998-01-16 2002-08-24 Japan Tobacco Inc
US6124500A (en) * 1998-03-09 2000-09-26 Rohm And Haas Company Process for synthesizing benzoic acids
FR2776292B1 (fr) * 1998-03-20 2004-09-10 Oncopharm Cephalotaxanes porteurs de chaine laterale et leur procede de synthese
AU6852998A (en) * 1998-04-16 1999-11-08 Nagase & Company, Ltd. Process for preparing chloro alcohol derivatives and intermediates
ES2235492T3 (es) 1998-06-19 2005-07-01 Vertex Pharmaceuticals Incorporated Inhibidores de aspartil proteasa de tipo sulfonamida.
WO2000002862A1 (en) 1998-07-08 2000-01-20 G.D. Searle & Co. Retroviral protease inhibitors
US6107511A (en) * 1998-07-29 2000-08-22 Kaneka Corporation Process for the purification or isolation of (2S,3R)-1-halo-2-hydroxy-3-(protected amino)4-phenylthiobutanes or optical antipodes thereof
US7115584B2 (en) * 1999-01-22 2006-10-03 Emory University HIV-1 mutations selected for by β-2′,3′-didehydro-2′,3′-dideoxy-5-fluorocytidine
US7635690B2 (en) * 1999-01-22 2009-12-22 Emory University HIV-1 mutations selected for by β-2′,3′-didehydro-2′,3′-dideoxy-5-fluorocytidine
US6319946B1 (en) 1999-02-12 2001-11-20 Vertex Pharmaceuticals Incorporated Inhibitors of aspartyl protease
US6566560B2 (en) 1999-03-22 2003-05-20 Immugen Pharmaceuticals, Inc. Resorcinolic compounds
BR0009200A (pt) 1999-03-22 2001-12-26 Immugen Pharmaceuticals Inc Compostos e composições para o tratamento dedoenças associada com disfunção imune
JP2003504383A (ja) * 1999-07-20 2003-02-04 メルク エンド カムパニー インコーポレーテッド アルファ−ヒドロキシ−ガンマ−［［（炭素環式−又はヘテロ環式−置換）アミノ］カルボニル］アルカンアミド誘導体及びこれらの使用
US6589962B1 (en) 1999-07-20 2003-07-08 Merck & Co., Inc. Alpha-hydroxy-gamma-[[(carbocyclic-or heterocyclic-substituted)amino]carbonyl]alkanamide derivatives and uses thereof
KR100339831B1 (ko) * 1999-08-18 2002-06-07 김태성 신규의 에틸 아지리딘 유도체 및 그 제조방법
US6403799B1 (en) 1999-10-21 2002-06-11 Agouron Pharmaceuticals, Inc. Methods for the preparation of intermediates in the synthesis of HIV-protease inhibitors
AU777824B2 (en) 1999-11-24 2004-11-04 Merck Sharp & Dohme Corp. Gamma-hydroxy-2-(fluoroalkylaminocarbonyl)-1- piperazinepentanamides as HIV protease inhibitors
CN100536833C (zh) 2000-01-19 2009-09-09 艾博特公司 改良药物配方
EP1265849B1 (de) 2000-03-23 2006-10-25 Elan Pharmaceuticals, Inc. Verbindungen und verfahren zur behandlung der alzheimerschen krankheit
US6992081B2 (en) 2000-03-23 2006-01-31 Elan Pharmaceuticals, Inc. Compounds to treat Alzheimer's disease
WO2001082919A2 (en) 2000-05-04 2001-11-08 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Methods of and compounds for inhibiting calpains
US20020198207A1 (en) * 2000-05-18 2002-12-26 Kath John Charles Novel Hexanoic acid derivatives
PE20020276A1 (es) 2000-06-30 2002-04-06 Elan Pharm Inc COMPUESTOS DE AMINA SUSTITUIDA COMO INHIBIDORES DE ß-SECRETASA PARA EL TRATAMIENTO DE ALZHEIMER
US6846813B2 (en) * 2000-06-30 2005-01-25 Pharmacia & Upjohn Company Compounds to treat alzheimer's disease
KR20030058959A (ko) * 2000-06-30 2003-07-07 엘란 파마슈티칼스, 인크. 알츠하이머병을 치료하기 위한 화합물
US20030096864A1 (en) * 2000-06-30 2003-05-22 Fang Lawrence Y. Compounds to treat alzheimer's disease
EP1666452A2 (de) 2000-06-30 2006-06-07 Elan Pharmaceuticals, Inc. Verbindungen zur Behandlung der Alzheimerischen Krankheit
US7425537B2 (en) * 2000-08-22 2008-09-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services SH2 domain binding inhibitors
US20020137802A1 (en) * 2000-09-28 2002-09-26 Travis Craig R. Methods and compounds for inhibiting eicosanoid metabolism and platelet aggregation
AU2002213429A1 (en) * 2000-09-28 2002-04-08 Immugen Pharmaceuticals, Inc. Antiviral methods and compounds
IT1318986B1 (it) * 2000-10-09 2003-09-19 Archimica S P A Ora Clariant L Procedimento per la preparazione di (s)-n-terbutil-1,2,3,4-tetraidroisochinolin-3-carbossiammide.
EP2479578A1 (de) * 2000-10-19 2012-07-25 Target Discovery, Inc. Massendefektkennzeichnung zur Bestimmung von Oligomersequenzen
JPWO2002064553A1 (ja) * 2001-02-14 2004-06-10 呉羽化学工業株式会社 ハロゲノアルコール誘導体の製造方法
HN2002000136A (es) 2001-06-11 2003-07-31 Basf Ag Inhibidores de la proteasa del virus hiv, compuestos que contienen a los mismos, sus usos farmaceuticos y los materiales para su sintesis
BR0210721A (pt) * 2001-06-27 2004-07-20 Elan Pharm Inc Composto, sal ou éster farmaceuticamente aceitável, método para fabricar um composto, e, método para tratar um paciente que tem, ou para evitar que o paciente adquira uma doença ou condição
US20070213407A1 (en) * 2001-06-29 2007-09-13 Elan Pharmaceuticals And Pharmacia & Upjohn Company Llc Compounds to treat Alzheimer's disease
US20030191121A1 (en) * 2001-08-09 2003-10-09 Miller Ross A. Piperazine carboxamide intermediates of HIV protease inhibitors and processes for their preparation
US20030068655A1 (en) * 2001-09-12 2003-04-10 Protiveris, Inc. Microcantilever apparatus and methods for detection of enzymes
US6696494B2 (en) 2001-10-22 2004-02-24 Enanta Pharmaceuticals, Inc. α-hydroxyarylbutanamine inhibitors of aspartyl protease
EP1490090A4 (de) 2002-02-22 2006-09-20 New River Pharmaceuticals Inc Wirkstoff-abgabesystem und verfahren zum schutz und zur verabreichung von wirkstoffen
US20040067216A1 (en) * 2002-02-22 2004-04-08 Karki Shyam B. Hiv protease inhibitors supported on cation exchange resins for oral administration
US7157489B2 (en) * 2002-03-12 2007-01-02 The Board Of Trustees Of The University Of Illinois HIV protease inhibitors
US20030232101A1 (en) * 2002-03-18 2003-12-18 Immugen Pharmaceuticals, Inc. Topical formulations of resorcinols and cannibinoids and methods of use
DE10212885A1 (de) * 2002-03-22 2003-10-02 Bayer Ag Verfahren zur Herstellung von 3-Hydroxy-2-methylbenzoesäure
DE10226219A1 (de) * 2002-06-13 2004-01-08 Bayer Ag Verfahren zur Herstellung von 3-Acyloxy-2-methylbenzoesäuren
EP1371626A3 (de) * 2002-06-13 2004-07-21 Bayer Chemicals AG Verfahren zur Herstellung von 3-Alkoxy-2-methylbenzoesäuren
CA2393720C (en) 2002-07-12 2010-09-14 Eli Lilly And Company Crystalline 2,5-dione-3-(1-methyl-1h-indol-3-yl)-4-[1-(pyridin-2-ylmethyl)piperidin-4-yl]-1h-indol-3-yl]-1h-pyrrole mono-hydrochloride
DE50302717D1 (de) * 2002-08-21 2006-05-11 Lanxess Deutschland Gmbh Chirale Diphosphorverbindungen und deren Übergangsmetallkomplexe
JP4697962B2 (ja) 2003-02-13 2011-06-08 ウェルスタット セラピューティクス コーポレイション 代謝性障害の処置のための化合物
SG145572A1 (en) * 2003-05-08 2008-09-29 Pfizer Intermediates useful in the synthesis of hiv-protease inhibitors and methods for preparing the same
EP1652525A4 (de) * 2003-07-15 2008-10-01 Arigen Inc Anti-coronavirus-arzneimittel
US7211588B2 (en) * 2003-07-25 2007-05-01 Zentaris Gmbh N-substituted indolyl-3-glyoxylamides, their use as medicaments and process for their preparation
US8377952B2 (en) * 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
US8025899B2 (en) * 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
CN101027062A (zh) 2004-07-27 2007-08-29 吉里德科学公司 Hiv抑制剂化合物的膦酸酯类似物
US8367832B2 (en) * 2004-08-23 2013-02-05 Mylan Laboratories Limited Crystalline forms of Nelfinavir mesylate
ATE540675T1 (de) 2005-04-01 2012-01-15 Wellstat Therapeutics Corp Verbindungen zur behandlung von stoffwechselstörungen
US8076514B2 (en) 2005-07-20 2011-12-13 Eli Lilly And Company Phenyl compounds and their use in the treatment of Type II diabetes
EP1910317B1 (de) 2005-07-20 2013-07-03 Eli Lilly And Company 1-amino-verbundene verbindungen
KR20080089453A (ko) 2006-01-25 2008-10-06 웰스태트 테러퓨틱스 코포레이션 물질대사 장애의 치료용 화합물
EP1976377A4 (de) 2006-01-25 2010-06-23 Wellstat Therapeutics Corp Verbindungen zur behandlung von stoffwechselstörungen
US20090176885A1 (en) 2006-02-02 2009-07-09 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
JP4831410B2 (ja) * 2006-02-28 2011-12-07 東亞合成株式会社 抗ウイルス性ペプチドおよび抗ウイルス剤
JP4788958B2 (ja) * 2006-02-28 2011-10-05 東亞合成株式会社 抗ウイルス性ペプチドおよびその利用
ES2596532T3 (es) * 2006-03-16 2017-01-10 Second Genome, Inc. Compuestos de bicicloheteroarilo como moduladores de P2X7 y usos de los mismos
WO2008033466A2 (en) * 2006-09-14 2008-03-20 Combinatorx (Singapore) Pre. Ltd. Compositions and methods for treatment of viral diseases
WO2008041087A1 (en) * 2006-10-06 2008-04-10 Aurobindo Pharma Limited An improved process for preparation of amorphous nelfinavir mesylate
AU2008226823B2 (en) 2007-03-12 2014-03-13 Nektar Therapeutics Oligomer-protease inhibitor conjugates
AR067183A1 (es) * 2007-06-29 2009-09-30 Gilead Sciences Inc Composiciones terapeuticas y metodos, usos y equipos
KR20100028656A (ko) * 2007-06-29 2010-03-12 길리애드 사이언시즈, 인코포레이티드 치료 조성물 및 그의 용도
WO2009036341A2 (en) * 2007-09-14 2009-03-19 The Regents Of The University Of Michigan Compositions and methods relating to hiv protease inhibition
JP2010540517A (ja) * 2007-09-25 2010-12-24 メルク・シャープ・エンド・ドーム・コーポレイション Ｈｉｖプロテアーゼ阻害剤
US9095620B2 (en) * 2008-03-12 2015-08-04 Nektar Therapeutics Reagents
US8829058B2 (en) 2008-03-13 2014-09-09 Wellstat Therapeutics Corporation Compounds and method for reducing uric acid
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
CA2745295C (en) 2008-12-09 2017-01-10 Gilead Sciences, Inc. Modulators of toll-like receptors
EP3210603A1 (de) * 2008-12-11 2017-08-30 Shionogi & Co., Ltd Synthese von carbamoylpyridon-hiv-integrase-hemmern und zwischenprodukte
TW201031675A (en) 2008-12-23 2010-09-01 Pharmasset Inc Synthesis of purine nucleosides
NZ593649A (en) * 2008-12-23 2013-11-29 Gilead Pharmasset Llc Nucleoside analogs
CA2748057C (en) * 2008-12-23 2018-07-03 Pharmasset, Inc. Nucleoside phosphoramidates
JP2012528160A (ja) 2009-05-27 2012-11-12 メルク・シャープ・エンド・ドーム・コーポレイション Ｈｉｖプロテアーゼ阻害薬
EP2440249A2 (de) 2009-06-12 2012-04-18 Nektar Therapeutics Kovalente konjugate mit einem protease-inhibitor, einem wasserlöslichen nicht-peptidischen oligomer und einem lipophilen teil
US10640457B2 (en) 2009-12-10 2020-05-05 The Trustees Of Columbia University In The City Of New York Histone acetyltransferase activators and uses thereof
ES2764999T3 (es) * 2009-12-10 2020-06-05 Univ Columbia Activadores de histona acetiltransferasa y usos de los mismos
DE102010004957A1 (de) 2010-01-14 2011-07-21 Universitätsklinikum Jena, 07743 Biologisch wirksame Moleküle zur Beeinflussung von Virus-, Bakterien-, Parasiten-infizierten Zellen und/oder Tumorzellen und Verfahren zu deren Anwendung
US20110223131A1 (en) 2010-02-24 2011-09-15 Gilead Sciences, Inc. Antiviral compounds
US8247436B2 (en) 2010-03-19 2012-08-21 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
KR101715981B1 (ko) 2010-03-31 2017-03-13 길리애드 파마셋 엘엘씨 뉴클레오사이드 포스포르아미데이트
TWI577377B (zh) 2010-09-16 2017-04-11 Ｖｉｉｖ醫療保健公司 醫藥組合物
WO2012055031A1 (en) 2010-10-28 2012-05-03 Merck Canada Inc. Hiv protease inhibitors
US9133157B2 (en) 2011-10-26 2015-09-15 Merck Canada Inc. HIV protease inhibitors
CN104755475B (zh) 2012-09-11 2016-12-28 默沙东公司 Hiv蛋白酶抑制剂
EP2912047B1 (de) 2012-10-29 2016-08-24 Cipla Limited Antivirale phosphonatanaloga und verfahren zur herstellung davon
RU2505286C1 (ru) 2012-12-29 2014-01-27 Открытое Акционерное Общество "Фармасинтез" Фармацевтическая композиция для лечения вич-инфекции, способ ее получения и способ лечения
WO2015013835A1 (en) 2013-07-31 2015-02-05 Merck Sharp & Dohme Corp. Piperazine derivatives as hiv protease inhibitors
RU2543322C1 (ru) * 2013-09-19 2015-02-27 Открытое Акционерное Общество "Фармасинтез" Фармацевтическая композиция для лечения вич-инфекции, способ ее получения и способ лечения
US9737545B2 (en) 2013-12-19 2017-08-22 Merck Sharp & Dohme Corp. HIV protease inhibitors
US9834526B2 (en) 2013-12-19 2017-12-05 Merck Sharp & Dohme Corp. HIV protease inhibitors
WO2015134366A1 (en) 2014-03-06 2015-09-11 Merck Sharp & Dohme Corp. Hiv protease inhibitors
US10138255B2 (en) 2014-03-10 2018-11-27 Merck Sharp & Dohme Corp. Piperazine derivatives as HIV protease inhibitors
WO2016001907A1 (en) 2014-07-02 2016-01-07 Prendergast Patrick T Mogroside iv and mogroside v as agonist/stimulator/un-blocking agent for toll-like receptor 4 and adjuvant for use in human/animal vaccine and to stimulate immunity against disease agents.
TWI733652B (zh) 2014-07-11 2021-07-21 美商基利科學股份有限公司 用於治療ＨＩＶ之ｔｏｌｌ樣受體調節劑
WO2016069955A1 (en) 2014-10-29 2016-05-06 Wisconsin Alumni Research Foundation Boronic acid inhibitors of hiv protease
WO2017048727A1 (en) 2015-09-15 2017-03-23 Gilead Sciences, Inc. Modulators of toll-like recptors for the treatment of hiv
US10539397B2 (en) 2017-04-12 2020-01-21 Wilcox Industries Corp. Modular underwater torpedo system
EP3684767A1 (de) 2017-09-22 2020-07-29 Jubilant Epipad LLC Heterocyclische verbindungen als pad-inhibitoren
DK3697785T3 (da) 2017-10-18 2023-04-03 Jubilant Epipad LLC Imidazo-pyridine forbindelser som pad-inhibitorer
SG11202004143XA (en) 2017-11-06 2020-06-29 Jubilant Prodel LLC Pyrimidine derivatives as inhibitors of pd1/pd-l1 activation
US11459338B2 (en) 2017-11-24 2022-10-04 Jubilant Episcribe Llc Heterocyclic compounds as PRMT5 inhibitors
SG11202008950PA (en) 2018-03-13 2020-10-29 Jubilant Prodel LLC Bicyclic compounds as inhibitors of pd1/pd-l1 interaction/activation
US20230157998A1 (en) 2020-03-06 2023-05-25 Pfizer Inc. Methods of Inhibiting SARS-CoV-2 Replication and Treating Corona Virus Disease 2019
WO2021209563A1 (en) 2020-04-16 2021-10-21 Som Innovation Biotech, S.A. Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2448392A1 (fr) * 1979-02-12 1980-09-05 Vilbiss Toussaint De Dispositif automatique pour la projection de produits de revetement
US5142056A (en) * 1989-05-23 1992-08-25 Abbott Laboratories Retroviral protease inhibiting compounds
IL89900A0 (en) * 1988-04-12 1989-12-15 Merck & Co Inc Hiv protease inhibitors useful for the treatment of aids and pharmaceutical compositions containing them
CA1340588C (en) * 1988-06-13 1999-06-08 Balraj Krishan Handa Amino acid derivatives
IL91307A0 (en) * 1988-08-24 1990-03-19 Merck & Co Inc Hiv protease inhibitors and pharmaceutical compositions for the treatment of aids containing them
EP0361341A3 (de) * 1988-09-28 1991-07-03 Miles Inc. Therapeutika für AIDS auf der Basis von HIV-Protease-Inhibitoren
US5063208A (en) * 1989-07-26 1991-11-05 Abbott Laboratories Peptidyl aminodiol renin inhibitors
WO1991008221A1 (en) * 1989-12-04 1991-06-13 Wisconsin Alumni Research Foundation Peptide inhibitors of hiv protease
GB8927915D0 (en) * 1989-12-11 1990-02-14 Hoffmann La Roche Novel alcohols
GB8927913D0 (en) * 1989-12-11 1990-02-14 Hoffmann La Roche Amino acid derivatives
CA2032259A1 (en) * 1989-12-18 1991-06-19 Wayne J. Thompson Hiv protease inhibitors useful for the treatment of aids
CA2056911C (en) * 1990-12-11 1998-09-22 Yuuichi Nagano Hiv protease inhibitors
HUT60282A (en) * 1991-02-08 1992-08-28 Sankyo Co Process for producing new beta-amino-alpha-hydroxycarboxylic acid derivatives and pharmaceutical compositions comprising such compounds
US5235039A (en) * 1991-06-10 1993-08-10 Eli Lilly And Company Substrates for hiv protease
CN1071930A (zh) 1991-07-10 1993-05-12 伊莱利利公司 用作治疗艾滋病的人免疫缺陷病毒蛋白酶的抑制剂
US5508407A (en) * 1991-07-10 1996-04-16 Eli Lilly And Company Retroviral protease inhibitors
US5220796A (en) 1991-07-15 1993-06-22 The Boc Group, Inc. Adsorption condensation solvent recovery system
DE4126482A1 (de) * 1991-08-10 1993-02-11 Bayer Ag (alpha)-trifluormethyl-substituierte, gesaettigt-bicyclische amine und verfahren zu deren herstellung
US5516784A (en) * 1991-08-13 1996-05-14 Schering Corporation Anti-HIV (AIDS) agents
EP0534511A1 (de) * 1991-08-16 1993-03-31 Merck & Co. Inc. HIV-Protease-Hemmer zur Behandlung von AIDS
US5256783A (en) 1991-09-18 1993-10-26 Hoffmann-La Roche Inc. Method for producing 2-isoquinoline compounds
WO1993008184A1 (en) * 1991-10-23 1993-04-29 Merck & Co., Inc. Hiv protease inhibitors
ZA929869B (en) * 1991-12-20 1994-06-20 Syntex Inc Hiv protease inhibitors
DK0560268T3 (da) * 1992-03-13 1995-06-12 Bio Mega Boehringer Ingelheim Substituerede pipecolinsyrederivater som HIV-proteasehæmmere
CA2136312A1 (en) * 1992-05-21 1993-11-25 Michael Clare Retroviral protease inhibitors
EP0810209B1 (de) * 1992-08-25 2002-06-05 G.D. Searle & Co. Hydroxyethylaminosulfonamide verwendbar als Inhibitoren retroviraler Proteasen
IS2334B (is) * 1992-09-08 2008-02-15 Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) Aspartyl próteasi hemjari af nýjum flokki súlfonamíða
MX9308025A (es) * 1992-12-22 1994-08-31 Lilly Co Eli Compuestos inhibidores de la proteasa del virus dela inmunodeficiencia humana, procedimiento para supreparacion y formulacion farmaceutica que los contiene.
MX9308016A (es) 1992-12-22 1994-08-31 Lilly Co Eli Compuestos inhibidores de la proteasa del virus de la inmunodeficiencia humana, procedimiento para su preparacion y formulacion farmaceutica que los contiene.
US5733906A (en) * 1993-10-12 1998-03-31 Eli Lilly And Company Inhibitors of HIV Protease useful for the treatment of Aids
US5846993A (en) * 1992-12-22 1998-12-08 Agouron Pharmaceuticals, Inc. HIV protease inhibitors
US5491166A (en) * 1992-12-22 1996-02-13 Eli Lilly And Company Inhibitors of HIV protease useful for the treatment of AIDS
US5434265A (en) * 1992-12-22 1995-07-18 Eli Lilly And Company Inhibitors of HIV protease
US5554653A (en) * 1992-12-22 1996-09-10 Eli Lilly And Company Inhibitors of HIV protease useful for the treatment of AIDS
US5484926A (en) * 1993-10-07 1996-01-16 Agouron Pharmaceuticals, Inc. HIV protease inhibitors
EP0604182B1 (de) 1992-12-22 2000-10-11 Eli Lilly And Company HIV Protease hemmende Verbindungen
US5475136A (en) * 1992-12-22 1995-12-12 Eli Lilly And Company Inhibitors of HIV protease useful for the treatment of AIDS
US5480887A (en) * 1994-02-02 1996-01-02 Eli Lilly And Company Protease inhibitors
US5527829A (en) * 1994-05-23 1996-06-18 Agouron Pharmaceuticals, Inc. HIV protease inhibitors

Also Published As

Publication number Publication date
US6271235B1 (en) 2001-08-07
DE69434214T2 (de) 2005-06-02
ATE222240T1 (de) 2002-08-15
NO961382D0 (no) 1996-04-03
KR100190517B1 (en) 1999-06-01
MD1507F2 (en) 2000-07-31
BG62567B1 (bg) 2000-02-29
BG100455A (en) 1997-09-30
CA2268709C (en) 2008-03-25
US5834467A (en) 1998-11-10
JP2951724B2 (ja) 1999-09-20
US5952343A (en) 1999-09-14
PL313871A1 (en) 1996-07-22
HK1013650A1 (en) 1999-09-03
CA2173328C (en) 1999-08-31
DE69434977D1 (de) 2007-07-05
JPH11310573A (ja) 1999-11-09
GEP20002209B (en) 2000-08-25
DE69431193T2 (de) 2002-12-12
EP0889036A1 (de) 1999-01-07
US5837710A (en) 1998-11-17
HU227885B1 (en) 2012-05-29
EP0889036B1 (de) 2004-12-29
FI114794B (fi) 2004-12-31
RO119363B1 (ro) 2004-08-30
EP0722439B1 (de) 2002-08-14
DE69434214D1 (de) 2005-02-03
MY138860A (en) 2009-08-28
EP0722439A1 (de) 1996-07-24
JP3703647B2 (ja) 2005-10-05
AP9600844A0 (en) 1996-07-31
SK43996A3 (en) 1997-01-08
AP600A (en) 1997-07-23
BR9407782A (pt) 1997-03-18
CZ100496A3 (en) 1996-09-11
HUT75652A (en) 1997-05-28
DK0889036T3 (da) 2005-02-28
PT722439E (pt) 2002-12-31
GEP20084497B (en) 2008-09-25
ATE362918T1 (de) 2007-06-15
DE69434977T2 (de) 2008-03-13
NZ329626A (en) 1999-08-30
SI0722439T1 (en) 2002-10-31
US5827858A (en) 1998-10-27
CN1195737C (zh) 2005-04-06
UA56984C2 (uk) 2003-06-16
CN1131942A (zh) 1996-09-25
CA2268709A1 (en) 1995-04-13
US20030216569A1 (en) 2003-11-20
EP1340744A2 (de) 2003-09-03
SK284116B6 (sk) 2004-09-08
ES2181725T3 (es) 2003-03-01
US6525215B2 (en) 2003-02-25
DK0722439T3 (da) 2002-12-16
ES2287387T3 (es) 2007-12-16
ES2236849T3 (es) 2005-07-16
US5827859A (en) 1998-10-27
US6162812A (en) 2000-12-19
EE05399B1 (et) 2011-04-15
SK284115B6 (sk) 2004-09-08
ATE286025T1 (de) 2005-01-15
CA2173328A1 (en) 1995-04-13
EP1340744B1 (de) 2007-05-23
HU9600908D0 (en) 1996-05-28
CN1046269C (zh) 1999-11-10
PT889036E (pt) 2005-05-31
TW432049B (en) 2001-05-01
US20020077338A1 (en) 2002-06-20
US5484926A (en) 1996-01-16
TJ339B (en) 2002-07-01
WO1995009843A1 (en) 1995-04-13
JPH09501443A (ja) 1997-02-10
US5859002A (en) 1999-01-12
UY23840A1 (es) 1994-10-21
NO961382L (no) 1996-04-09
AU7967494A (en) 1995-05-01
NZ275633A (en) 1998-03-25
CZ290417B6 (cs) 2002-07-17
EP1340744A3 (de) 2003-12-03
US6693199B2 (en) 2004-02-17
HU226814B1 (en) 2009-11-30
HK1056172A1 (en) 2004-02-06
EE9600091A (et) 1996-12-16
HK1014950A1 (en) 1999-10-08
SI0889036T1 (en) 2005-04-30
OA10718A (en) 2001-11-02
MD1507G2 (ro) 2001-04-30
HU0900219D0 (en) 2009-06-29
US5827891A (en) 1998-10-27
FI961449A (fi) 1996-05-29
RU2139280C1 (ru) 1999-10-10
US5824688A (en) 1998-10-20
NO307050B1 (no) 2000-01-31
CN1262272A (zh) 2000-08-09
PL185647B1 (pl) 2003-06-30
US5852043A (en) 1998-12-22
AU694746B2 (en) 1998-07-30
FI961449A0 (fi) 1996-03-29

Similar Documents

Publication Publication Date Title
DE69431193D1 (en) Hiv - protease inhibitoren
DE69433664D1 (en) Foetal-sensor
DE69400639D1 (en) Rehydratationsgetraenk
DE69426415D1 (en) Intrapulmonares hormonabgabesystem
DE69421914D1 (en) Ekg-sensor
DE69401926D1 (en) Hydroxamsäurederivate
DE69406448D1 (en) Luftreinigungsgerät
DE69405713D1 (en) Carbonylierungsverfahren
DE69412242D1 (en) Orthopädisches gussmaterial
DE59407177D1 (en) 2-fluorcycloyhexen-derivate
DE69423875D1 (en) Hydrodealkylierungsverfahren
GB2278202B (en) Aquameter
DE69429512D1 (en) Thermoresistente alpha-1-antitrypsinmütante
DE59408644D1 (en) Jacquardmaschine
GB2274735B (en) Membraphone
DE69408437D1 (en) Oxychlorierungsverfahren
EP0730584A4 (de) 3-acylaminobenzodiazepine
DE59408733D1 (en) Metallhalogenidentladungslampe
GB2277797B (en) Starcloth
HUT69872A (en) Reaper-thresher
GB2274048B (en) Headcollars
DE69412128D1 (en) Kühlcontainer
DE69407946D1 (en) Oxychlorierungskatalysator
DE69425743D1 (en) Faserreaktive anthrachinon-farbstoffe
DE69410761D1 (en) Polyacetalharzzusammensetzung

Legal Events

Date Code Title Description
8364 No opposition during term of opposition